Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Tiny electric pulses tested to curb pain after knee replacement

NCT ID NCT05416294

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers are testing whether a device that sends mild electrical pulses through the skin, called PENS, can ease pain after total knee replacement. Patients having knee replacement surgery receive either the real PENS device or a sham device, both alongside standard pain medicines. The trial measures pain scores right after surgery and during movement in the days that follow, and tracks how much opioid painkiller patients use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PENS treatment using the Primary Relief device
What this could lead to
If it works, PENS could become an added option for easing pain after knee replacement and cutting how much opioid painkiller patients need.
What could go wrong
This is an early device study, so results may not hold up in larger groups. Nerve stimulation can cause skin irritation or discomfort at the electrode site, and some patients may not respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Expected to start

Aug 2022

An estimate. Start dates often move.

Expected to finish

Dec 2024

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients undergoing TKR under regional or general anesthesia and femoral nerve block who consent to participate in the study. Exclusion Criteria: * ASA 3 or 4 * Those receiving psychiatric medication * Those with infection at the site of application. The following data will be collected * Intraoperative use of local anesthetics, opioids and other analgesics * Postoperative details as to the time of application of the device. NPRS in both the groups at multiple intervals, on demand analgesic requirement, overall analgesic consumption during the study period, quality of life questionnaire at the end of the study period and relevant postoperative complications will be noted. * Rescue analgesics will be considered for breakthrough pain or NPRS \> 4. Intravenous Tramadol 50mg will be the first rescue analgesic and if pain is not relieved with Tramadol, opiods will be considered. Non steroidal anti inflammatory drugs will be considered to supplement the above medications if there is no contraindication and if need arises. * NPRS score will be noted at multiple intervals for 10 days. * Any nausea, vomiting, giddiness, intolerance to the device will also be noted. * During the follow up, quality of life questionnaire would be administered and the result noted. The device will be removed after 10 days of its application. Any redness at the site of application or pain at the site are noted. The study will end with the removal of the device.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arthroplasty, knee replacement are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.